Clinical Trials Logo

Clinical Trial Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06257485
Study type Observational
Source Montefiore Medical Center
Contact
Status Active, not recruiting
Phase
Start date September 23, 2023
Completion date October 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Recruiting NCT06086353 - A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Active, not recruiting NCT06321523 - A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Completed NCT05233163 - SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy Phase 4
Not yet recruiting NCT06101108 - Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
Completed NCT04814186 - A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase 4
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT05259072 - carDIo-ttranSSfOrm nucLEar Imaging Study Phase 3
Recruiting NCT06183931 - Study of ALXN2220 Versus Placebo in Adults With ATTR-CM Phase 3
Recruiting NCT06328075 - Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT06291805 - Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Terminated NCT04424914 - Global Prevalence of ATTR-CM in Participants With HFpEF N/A
Recruiting NCT06194825 - EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT06372301 - Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy N/A